Nuwellis (NUWE) Stock Price, News & Analysis

Company Overview

Nuwellis, Inc. is a medical device company focused on fluid management therapies for patients with fluid overload. The company develops and commercializes ultrafiltration technologies designed to remove excess salt and fluid from the blood when conventional diuretic therapy may be inadequate or poorly tolerated.

Nuwellis’ principal product is the Aquadex system, including the Aquadex FlexFlow system, a compact ultrafiltration platform used in hospital settings. The system is intended for temporary extracorporeal fluid removal in patients with conditions such as fluid overload associated with heart failure, renal dysfunction, and other critical-care needs. Nuwellis has also promoted applications of its technology in pediatric care.

The company was formerly known as CHF Solutions, Inc. and adopted the Nuwellis name in 2020. Its products are primarily marketed to hospitals and healthcare providers in the United States. Nuwellis is headquartered in Minneapolis, Minnesota, and focuses on expanding clinical applications and adoption of its ultrafiltration technology.

Key Stats

• Today's Range: $4.43 to $4.68
• 50-Day Range: $2.90 to $9.81
• 52-Week Range: $2.52 to $1,556.07
• Volume: 31,309 shs
• Average Volume: 2.11 million shs
• Market Capitalization: $2.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Nuwellis Stock Analysis - MarketRank™

Nuwellis scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Nuwellis has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Nuwellis has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuwellis is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuwellis is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuwellis has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.49% of the float of Nuwellis has been sold short.

Short Interest Ratio / Days to Cover

Nuwellis has a short interest ratio ("days to cover") of 0.57, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nuwellis has recently decreased by 46.63%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuwellis does not currently pay a dividend.

Dividend Growth

Nuwellis does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.45

News Sentiment

Nuwellis has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Nuwellis this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for NUWE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nuwellis insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.60% of the stock of Nuwellis is held by insiders.

Percentage Held by Institutions

3.13% of the stock of Nuwellis is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/08/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:NUWE
• CIK: 1506492
• Web: www.nuwellis.com
• Phone: (952) 345-4200
• Fax: N/A
• Employees: 38
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1,193.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.52 million
• Net Margins: -123.38%
• Pretax Margin: -125.63%
• Return on Equity: -623.14%
• Return on Assets: -147.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.97
• Quick Ratio: 1.54

Sales & Book Value

• Annual Sales: $9.01 million
• Price / Sales: 0.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $497.85 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 541,000
• Free Float: 532,000
• Market Cap: $2.48 million
• Optionable: Not Optionable
• Beta: 0.03